Shares in Cambridge-based Vericel Corp (NSDQ:VCEL) surged last year after the FDA approved its bioresorbable scaffold for cartilage repair.

The product, Maci, is the first FDA-approved implant to use healthy cartilage tissue from a patient’s own knee to grow cells on the scaffold. Since the product’s approval in December 2016, surgeon uptake has helped to fuel the company’s continued growth, president & CEO Nick Colangelo told Drug Delivery Business News.